Combination therapy of alpha-glucosidase inhibitor and a sulfonylurea compound prolongs the duration of good glycemic control

被引：16

作者：

Matsumoto, K ^{[1
]}

Sera, Y ^{[1
]}

Abe, Y ^{[1
]}

Tominaga, T ^{[1
]}

Ueki, Y ^{[1
]}

Miyake, S ^{[1
]}

机构：

[1] Sasebo Chuo Hosp, Dept Diabet & Metab Endocrinol & Rheumatol, Nagasaki 8571195, Japan

来源：

METABOLISM-CLINICAL AND EXPERIMENTAL | 2002年 / 51卷 / 12期

关键词：

D O I：

10.1053/meta.2002.36310

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The aim of this study was to investigate whether combination therapy of alpha-glucosidase inhibitor and a sulfonylurea (SU) drug can prolong the duration of good glycemic control compared with SU alone in patients with type 2 diabetes. The open prospective study included 124 Japanese patients with type 2 diabetes and inadequate glycemic control (hemoglobin A(1c) [HbA(1c)] gt; 7.0%). Patients were given either voglibose plus a SU compound (glibenclamide or gliclazide, n = 61) or SU drug alone (n = 63). The first 6-month run-in period (targeted to HbA(1c) less than or equal to 7.0%) was followed by treatment for 3 years. The endpoint was deterioration of glycemic control (HbA(1c) greater than or equal to 8.0%). Fifty patients on combination therapy and 48 patients on SU alone completed the trial. During the follow-up, 21 patients on combination therapy and 30 patients on SU alone showed deterioration of glycemic control and reached the endpoint (P = .04). The combination therapy significantly prolonged the duration of good glycemic control (HbA(1c) < 8.0%) compared with SU alone by Kaplan-Meier estimated survival analysis using a log-rank test (P = .02). Thus, combination therapy with voglibose and a SU agent prolongs the duration of good glycemic control compared with SU alone in patients with type 2 diabetes. Copyright 2002, Elsevier Science (USA). All rights reserved.

引用

页码：1548 / 1552

页数：5

共 22 条

[21] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [J].

Turner, RC ;

Holman, RR ;

Cull, CA ;

Stratton, IM ;

Matthews, DR ;

Frighi, V ;

Manley, SE ;

Neil, A ;

McElroy, K ;

Wright, D ;

Kohner, E ;

Fox, C ;

Hadden, D ;

Mehta, Z ;

Smith, A ;

Nugent, Z ;

Peto, R ;

Adlel, AI ;

Mann, JI ;

Bassett, PA ;

Oakes, SF ;

Dornan, TL ;

Aldington, S ;

Lipinski, H ;

Collum, R ;

Harrison, K ;

MacIntyre, C ;

Skinner, S ;

Mortemore, A ;

Nelson, D ;

Cockley, S ;

Levien, S ;

Bodsworth, L ;

Willox, R ;

Biggs, T ;

Dove, S ;

Beattie, E ;

Gradwell, M ;

Staples, S ;

Lam, R ;

Taylor, F ;

Leung, L ;

Carter, RD ;

Brownlee, SM ;

Fisher, KE ;

Islam, K ;

Jelfs, R ;

Williams, PA ;

Williams, FA ;

Sutton, PJ .

LANCET, 1998, 352 (9131) :837-853

[22]

*WHO, 1985, TECH REP SER WHO, V727

← 1 2 3 →